Aptinyx Inc (APTX)

Trade APTX now with
10/27/2021 6:50:05 AM Aptinyx Closes Enrollment In Phase 2b Study Of NYX-2925 In Painful Diabetic Peripheral Neuropathy
10/20/2021 8:00:07 AM Aptinyx Appoints Gilmore O'Neill To Board
9/16/2021 6:40:35 AM Aptinyx Secures $50 Mln Growth Capital Credit Facility From K2 HealthVentures
4/6/2021 6:42:10 AM Aptinyx Recommences Phase 2 Study Of NYX-458; Sees Data From This Study In H2 Of 2022
1/19/2021 8:43:53 AM Aptinyx Publishes Review Article In Medicine In Drug Discovery Featuring Data On Novel NMDA Receptor Modulator, NYX-2925
1/4/2021 8:00:12 AM Aptinyx Announces Recommenced Patient Recruitment And Screening In Phase 2 Study Of NYX-2925
12/16/2020 8:37:46 AM Aptinyx Appoints Andy Kidd President And COO, Effective December 14
10/21/2020 11:05:51 PM Aptinyx Prices Public Offering Of 14 Mln Shares At $3.00/shr
9/28/2020 8:29:29 AM Aptinyx Recommences Patient Recruitment In Phase 2 Study Of NYX-2925 In Patients With Fibromyalgia